Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: August 2010

29 - Hyperprolactinemia

from PART II - INFERTILITY EVALUATION AND TREATMENT

Summary

Hyperprolactinemia has a detrimental effect on fertility both in women and men, leading to galactorrhea anovulation, amenorrhea, oligomenorrhea, impotence, gynecomastia, and low semen profile. Men with hyperprolactinemia not only show abnormal semen analysis but also abnormal histological structure of the testicles with distorted seminiferous tubules and abnormal sertoli cells. Many physiological and or pathological changes involving lactotroph cells can result in hyperprolactinemia. The majority of prolactinomas contains only lactotroph cells and produce prolactin in excess. Antihypertensive drugs like methyldopa and reserpine increases prolactin secretion. A dopamine agonist drug should usually be the first line of treatment for patients with hyperprolactinemia of any cause including lactotroph adenomas of all sizes. Bromocriptine, cabergoline, pergolide are the available dopamine agonists to treat hyperprolactinemia. Dopamine agonists decrease prolactin secretion and reduce the size of the lactotroph adenoma in more than 90 percent of patients. Surgical and radiation treatment are also useful.
REFERENCES
Davis, JR. Prolactin and reproductive medicine. Curr Opin Obstet Gynecol 2004;16(4):331–7.
Bole-Feysot, C, Goffin, V, Edery, M, Binart, N, Kelly, PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19:225–68.
Rizk, B. (Ed.). Ultrasonography in reproductive medicine and infertility, Cambridge: United Kingdom, Cambridge University Press 2008: (in press).
Scully, KM, Rosenfeld, MG. Pituitary development: regulatory codes in mammalian organogenesis. Science 22 2002;295(5563):2231–5.
Rosenfeld, MG, Briate, P, Dasen, J, Gleiberman, AS. Multistep. Signaling and transcriptional requirements for pituitary organogenesis in vivo. Recent Prog Horm Res 2000;55:1–13.
Cohen, , Wondisford, FE, Radovick, S. Role of Pit-1 in the gene expression of growth hormone, prolactin, and thyrotropin. Endocrinol Metab Clin North Am 1996;25:523–40.
Gonzalez-Parra, S, Chowen, JA, Garcia, SL, Argente, J. Ontogeny of pituitary transcription factor-1 (Pit-1), growth hormone (GH) and prolactin (PRL) mRNA levels in male and female rats and the differential expression of Pit-1 in lactotrophs and somatotrophs. J Neuroendocr 1996;8:211–25.
Sharp, ZD. Rat Pit-1 stimulates transcription in vitro by influencing preinitiation complex assembly. Biochem Biophys Res Commun 1995;206:40–5.
Nicoll, CS, Mayer, GL, Russell, SM. Structural features of prolactins and growth hormones that can be related to their biological properties. Endocr Rev 1986;7:169–203.
Goffin, V, Shiverick, KT, Kelly, PA, Martial, JA. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev 1996;17:385–410.
Horseman, ND, Yu-Lee, LY. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocrinol Rev 1994;15:627–49.
Bazan, JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934–8.
Berwaer, M, Monget, P, Peers, B, Mathy-Hartert, M, Bellefroid, E, Davis, JR, Belayew, A, Martial, JA. Multihormonal regulation of the human prolactin gene expression from 5000 bp of its upstream sequence. Mol Cell Endocrinol 1991;80:53–64.
Berwaer, M, Martial, JA, Davis, JR. Characterization of an up-stream promoter directing extrapituitary expression of the human prolactin gene. Mol Endocrinol 1994;8:635–42.
Peers, B, Voz, ML, Monget, P, Mathy-Hartert, M, Berwaer, M, et al. Regulatory elements controlling pituitary-specific expression of the human prolactin gene. Mol Cell Biol 1990;10:4690–700.
Truong, AT, Duez, C, Belayew, A, et al. Isolation and characterization of human prolactin gene. EMBO J 1984;3:429–37.
Sinha, YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1995;16:354–69.
Teilum, K, Hoch, JC, Goffin, V, Kinet, S, Martial, JA, Kragelund, BB. Solution structure of human prolactin. J Mol Biol 2005; 351(4):810–23.
Keeler, C, Dannies, PS, Hodsdon, ME. The tertiary structure and backbone dynamics of human prolactin. J Mol Biol 2003; 328(5):1105–21.
Kasic, SV, Ramos, IM, Selim, A, Gunz, G, Morange, S, Enjalbert, A, Martin, PM, Jaquet, P, Brue, T. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581–8.
Hattori, N, Ikekubo, K, Nakaya, Y, Kitagawa, K, Inagaki, C. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J Clin Endocrinol Metab 2005;90(5):3036–44. Epub 2005 Feb 1.
Leanos-Miranda, A, Cardenas-Mondragon, G, Rivera-Leanos, R, Ulloa-Aguirre, A, Goffin, V. Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinaemic patients. Clin Endocrinol (Oxf) 2006;65(2):146–53.
Bazan, JF. Haemopoietic receptors and helical cytokines. Immunol Today 1990;11: 350–54.
Rizk, B. Genetics of ovarian hyperstimulation syndrome. In Rizk, B (Ed.), Ovarian Hyperstimulation Syndrome. Cambridge, New York: Cambridge University Press, 2006; Chapter 4, pp. 79–91.
Schuler, , Nagel, RM, Gao, J, Horseman, ND, Kessler, MA. Prolactin receptor heterogeneity in fetal and maternal tissues. Endocrinology 1997;138:3187–94.
Bazan, JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934–8.
Kline, JB, Roehrs, H, Clevenger, CV. Functional characterization of the intermediate isoform of the human prolactin receptor. J Biol Chem 1999;274:35461–8.
Trott, JF, Hovey, RC, Koduri, S, Vonderhaar, BK. Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. J Mol Endocrinol 2003;30:31–47.
Herman, A, Bignon, C, Daniel, N, Grosclaude, J, Gertler, A, et al. Functional heterodimerization of prolactin and growth hormone receptors by ovine placental lactogen. J Biol Chem 2000;275:6295–301.
Veldhuis, JD, Johnson, ML. Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. J Clin Endocrinol Metab 1988;67(1):116–23.
Veldhuis, JD, Evans, WS, Stumpf, PG. Mechanisms that subserve estradiol's induction of increased prolactin concentrations: evidence of amplitude modulation of spontaneous prolactin secretory bursts. Am J Obstet Gynecol 1989;161(5):1149–58.
Freeman, ME, Kanyicska, B, Lerant, A, Nagy, G. 2000. Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523–631.
Berghe, G, Zegher, F, Veldhuis, JD, Wouters, P, Gouwy, S, Stockman, W, Weekers, F, Schetz, M, Lauwers, P, Bouillon, R, Bowers, CY. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf). 1997; 47(5):599–612.
Ben-Jonathan, N. Dopamine: a prolactin-inhibiting hormone. Endocr Rev 1985;6:564–589.
Lerant, A, Freeman, ME. Dopaminergic neurons in periventricular and arcuate nuclei of proestrous and ovariectomized rats: endogenous diurnal rhythm of Fos-related antigens expression. Neuroendocrinology 1997;65:436–445.
Binart, N, Helloco, C, Ormandy, CJ, Barra, J, Clement-Lacroix, P, et al. Rescue of preimplantatory egg development and embryo implantation in prolactin receptor-deficient mice after progesterone administration. Endocrinology 2000;141:2691–7.
Vacher, P, Mariot, P, Dufy-Barbe, L, Nikolics, K, Seeburg, PH, Kerdelhue, B, Dufy, B. The gonadotropin-releasing hormone associated peptide reduces calcium entry in prolactin-secreting cells. Endocrinology 1991;128(1):285–94.
Steele, MK. The role of brain angiotensin II in the regulation of luteinizing hormone and prolactin secretion. Trends Endocrinol Metab 1992;3:295–301.
Steele, MK, McCann, SM, Negro-Vilar, A. Modulation by dopamine and estradiol of the central effects of angiotensin II on anterior pituitary hormone release. Endocrinology 1982;111: 722–9.
Fessler, RG, Deyo, SN, Meltzer, HY, Miller, RJ. Evidence that the medial and dorsal raphe nuclei mediate serotonergically- induced increases in prolactin release from the pituitary. Brain Res 1984;299:231–7.
Dalcik, H, Phelps, CJ. Median eminence-afferent vasoactive intestinal peptide (VIP) neurons in the hypothalamus: localization by simultaneous tract tracing and immunocytochemistry. Peptides 1993;14:1059–66.
Braund, W, Roeger, DC, Judd, SJ. Synchronous secretion of luteinizing hormone and prolactin in the human luteal phase: neuroendocrine mechanisms. J Clin Endocrinol Metab 1984;58(2):293–7.
Christiansen, E, Veldhuis, JD, Rogol, AD, Stumpf, P, Evans, WS. Modulating actions of estradiol on gonadotropin-releasing hormone-stimulated prolactin secretion in postmenopausal individuals. Am J Obstet Gynecol 1987;157(2):320–5.
Kar, LD, Bethea, CL. Pharmacological evidence that serotonergic stimulation of prolactin secretion is mediated via the dorsal raphe nucleus. Neuroendocrinology 1982;35:225–30.
Takahashi, K, Yoshinoya, A, Arihara, Z, Murakami, O, Totsune, K, Sone, M, Sasano, H, Shibahara, S. Regional distribution of immunoreactive prolactin-releasing peptide in the human brain. Peptides 2000;21(10):1551–5.
Barber, MC, Clegg, RA, Finley, E, Vernon, RG, Flint, DJ. The role of growth hormone, prolactin and insulin-like growth factors in the regulation of rat mammary gland and adipose tissue metabolism during lactation. J Endocrinol 1992;135:195–202.
Tucker, HA. Lactation and its hormonal control. In Knobil, E, Neill, JD (Eds.), The Physiology of Reproduction, New York: Raven, 1994; pp. 1065–98.
Whitworth, NS. Lactation in humans. Psychoneuroendocrinology 1988;13(1–2):171–88. Review.
Speroff, L, Glass, RH, Kase, NG. Clinical Gynecologic Endocrinology and Infertility. Sixth edition. Baltimore, MD: Lippincott Williams and Wilkins, 1999. ISNB 0-683-30379-1.
Kruger, TH, Haake, P, Haverkamp, J, Kramer, M, Exton, MS, Saller, B, Leygraf, N, Hartmann, U, Schedlowski, M. Effects of acute prolactin manipulation on sexual drive and function in males. J Endocrinol 2003;179(3):357–65.
Sheth, AR, Mugatwala, PP, Shah, GV, et al. Occurrence of prolactin in human semen. Fertil Steril 1975;26:905–7.
Shah, GV, Desai, RB, Sheth, AR. Effect of prolactin on metabolism of human spermatozoa. Fertil Steril 1976;27:1292–4.
Hernandez-Andrade, E, Villanueva-Diaz, C, Ahued-Ahued, JR. Growth hormone and prolactin in maternal plasma and amniotic fluid during normal gestation. Rev Invest Clin. 2005;57(5):671–5.
Shennan, DB. Regulation of water and solute transport across mammalian plasma cell membranes by prolactin. J Dairy Res 1994;61:155–66.
Buskila, D, Shoenfeld, Y. Prolactin, bromocriptine and autoimmune diseases. Isr J Med Sci 1996;32:23–7.
Neidhart, M. Prolactin in autoimmune diseases. Proc Soc Exp Biol Med 1998;217:408–19.
Walker, SE, Allen, SH, McMurray, RW. Prolactin and autoimmune disease. Trends Endocrinol Metab 1993;4:147–51.
Roky, R, Paut-Pagano, L, Goffin, V, Kitahama, K, Valatx, JL, Kelly, PA, Jouvet, M. Distribution of prolactin receptors in the rat forebrain. Immunohistochemical study. Neuroendocrinology 1996;63:422–9.
Clapp, C, Martial, JA, Guzman, RC, Rentier-Delrue, F, Weiner, RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993;133:1292–9.
Clapp, C, Torner, L, Gutiérrez-Ospina, G, Alcántara, E, López-Gómez, FJ, Nagano, M, Kelly, PA, Mejía, S, Morales, MA, Martínez de la Escalera, G. The prolactin gene is expressed in the hypothalamic-neurohypophyseal system and the protein is processed into a 14-kDa fragment with activity like 16-kDa prolactin. Proc Natl Acad Sci USA 1994;91:10384–8.
Clapp, C, Weiner, RI. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 1992;130:1380–6.
Lissoni, P, Mandala, M, Rovelli, F, Casu, M, Rocco, F, et al. Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate- cancer-related hyperprolactinemia. Eur Urol 2000;37:569–72.
Leav, I, Merk, FB, Lee, KF, Loda, M, Mandoki, M, et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 1999;154:863–70.
Touraine, P, Martini, JF, Zafrani, B, Durand, JC, Labaille, F, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 1998; 83:667–74.
Wennbo, H, Gebre-Medhin, M, Gritli-Linde, A, Ohlsson, C, Isaksson, OG, et al. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997;100:2744–51.
Goffin, V, Touraine, P, Pichard, C, Bernichtein, S, Kelly, PA. Should prolactin be reconsidered as a therapeutic target in human breast cancer?Mol Cell Endocrinol 1999;151:79–87.
Cheung, CY. Prolactin suppresses luteininzing hormone secretion and pituitary responsiveness to luteinizing hormone-releasing hormone by a direct action at the anterior pituitary. Endocrinology 1983;113:632–638.
Milenkovic, L, D'Angelo, G, Kelly, PA, Weiner, RI. Inhibition of gonado tropin hormone-releasing hormone release by prolactin from GIT neuronal cell lines through prolactin receptors. Proc Natl Acad Sci USA 1994;91:1244–7.
Glass, MR, Shaw, RW, Butt, WR, et al. An abnormality of estrogen feedback in amenorrhea galactorrhea. Br Med J 1975;3:274–5.
McNeilly, KP, Glasier, A, Jonassen, J, et al. Evidence for direct inhibition of ovarian function by prolactin. J Reprod Fert 1982; 65:559–69.
Dorrington, JH, Gore-Langton, RE. Antigonadal action of prolactin: further studies on the mechanism of inhibition of follicle stimulating hormone-induced aromatase activity in rat granulosa cell cultures. Endocrinology 1982;110:1701–7.
McNatty KP, Sawers RS, McNeilly AS. A possible role for prolactin in control of steroid secretion by human graffian follicle. Nature. 1974 Aug 23;250(5468):653–5.
Del Pozo, E, Wyss, H, Tolis, G, et al. Prolactin and deficient luteal function. Obstet Gynecol 1979;53:282–6.
Feltus, FA, Groner, B, Melner, MH. Stat5-mediated regulation of the human type II 3α hydroxysteroid dehydrogenase isomerase gene activation by prolactin. Mol Endocrinol 1999;13:1084–93.
Cameron, DF, Murray, FT, Drylie, DD. Ultrastructural lesions in testes from hyperprolactinemic men. J Androl 1984;5:283–93.
Bahceci, M, Tuzcu, A, Bahceci, S, Tuzcu, S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?J Endocrinol Invest 2003;26(7):655–9.
Isik, AZ, Gulekli, B, Zorlu, CG, Ergin, T, Gokmen, O. Endocrinological and clinical analysis of hyperprolactinemic patients with and without ultrasonically diagnosed polycystic ovarian changes. Gynecol Obstet Invest 1997;43(3):183–5.
Tanaka, T, Fujimoto, S. Endocrinological environment of polycystic ovarian disease. Horm Res 1990;33 (Suppl. 2):5–9. Review.
Minakami, H, Abe, N, Oka, N, Kimura, K, Tamura, T, Tamada, T. Prolactin release in polycystic ovarian syndrome. Endocrinol Jpn 1988;35(2):303–10.
Tyson, JB, Ito, P, Guyda, H, et al. Studies of prolactin in human pregnancy. Am J Obstet Gynecol 1972;113:14.
Tyson, JE, Friesen, HG. Factors influencing the secretion of human prolactin and growth hormone in menstrual and gestational women. Am J Obstet Gynecol 1973;116:377.
Barberia, JM, Abu-FAdil, S, Kletzky, OA, Nakamura, RM, Mishell, DR Jr. Serum prolactin patterns in early human gestation. Am J Obstet Gynecol 1975;121:1107.
Kleinberg, DL, Noel, GL, Frantz, AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 1977; 296:589.
Alexander, JM, Biller, BMK, Bikkal, H, et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990;86:336.
Herman, V, Fagin, J, Gonsky, R, et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990;71:1427.
Zhang, X, Horwitz, GA, Heaney, AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999;84:761.
Ezzat, S, Zheng, L, Zhu, XF, et al. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002;109:69.
Corenblum, B, Sirek, AMT, Horvath, E, et al. Human mixed somatotrophic and lactotrophic pituitary adenomas. J Clin Endocrinol Metab 1976;42:857.
Mindermann, T, Wilson, CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 1994;41:359.
Delgrange, E, Trouillas, J, Maiter, D, et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 1997;82:2102.
Prosser, PR, Karam, JH, Townsend, JJ, et al. Prolactin-secreting pituitary adenomas in multiple endocrine adenomatosis, type 1. Ann Intern Med 1979;91:41.
Walker, JD, Grossman, A, Anderson, JV, et al. Malignant prolactinoma with extracranial metastases: a report of three cases. Clin Endocrinol 1993;38:411.
Petakov, MS, Damjanovic, SS, Nikolic-Durovic, MM, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998;21:184.
St-Jean, E, Blain, F, Comtois, R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996;44:305.
Barkan, AL, Chandler, WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the “high-dose hook effect.” Neurosurgery 1998;42:913.
David, SR, Taylor, CC, Kinon, BJ, Breier, A. The effects of olanzapine, rispiridone, and haloperiodol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22:1085.
Rivera, JL, Lal, S, Ettigi, P, et al. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 1976;5:273.
McCallum, RW, Sowers, JR, Hershman, JM, et al. Metoclopramide stimulates prolactin secretion in man. J Clin Endocrinol Metab 1976;42:1148.
Mancini, AM, Guitelman, A, Vargas, CA, et al. Effect of sulpiride on serum prolactin levels in humans. J Clin Endocrinol Metab 1976;42:181.
Sowers, JR, Sharp, B, McCallum, RW. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 181hydroxycorticosterone secretion in man. J Clin Endocrinol Metab 1982;54:869.
Steiner, J, Cassar, J, Maslliter, K, et al. Effect of methyldopa on prolactin and growth hormone. Br Med J 1976;1:1186.
Lee, PA, Kelly, MR, Wallin, JD. Increased prolactin levels during reserpine treatment of hypertensive patients. JAMA 1976;235:2316.
Fearrington, EL, Rand, CH, Rose, JD. Hyperprolactinemia- galactorrhea induced by verapamil. Am J Cardiol 1983;51:1466.
Veldhuis, JD, Borges, JLC, Drake, CR. Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on the thyrotropin- and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man. J Clin Endocrinol Metab 1985;60:144.
Cowen, PJ, Sargent, PA. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 1997;11:345.
Meltzer, H, Bastani, B, Jayathilake, K, Maes, M. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology 1997;17:1.
Honbo, KS, Herle, AJ, Kellett, KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med 1978;64:782.
Snyder, PJ, Jacobs, LS, Utiger, RD, Daughaday, WH. Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone. J Clin Invest 1973;52:2324.
Groff, TR, Shulkin, BL, Utiger, RD, Talbert, LM. Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism. Obstet Gynecol 1984;63:86S.
Grubb, MR, Chakeres, D, Malarkey, WB. Patients with primary hypothyroidism presenting as prolactinomas. Am J Med 1987;83:765.
Morley, JE, Hodgkinson, DH, Kalk, WJ. Galactorrhea and hyperprolactinemia associated with chest wall injury. J Clin Endocrinol Metab 1977;45:931.
Lim, VS, Kathpalia, SC, Frohman, . Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab 1979;48:101.
Sievertsen, GD, Lim, VS, Nakawatase, C, Frohman, . Metabolic clearance and secretion rates of human prolactin in normal subjects and patients with chronic renal failure. J Clin Endocrinol Metab 1980;50:846.
Schlechte, I, Dolan, K, Sherman, B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989;68:412.
Martin, TL, Kim, M, Malarkey, WB. The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab 1985;60:855.
Sluijmer, AV, Lappohn, RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Perth Steril 1992;58:72.
Carlson, HE, Markoff, E, Lee, DW. On the nature of serum prolactin in two patients with macroprolactinemia. Perth Steril 1992; 58:78.
Vallette-Kasic, S, Morange-Ramos, I, Selim, A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581.
Olukoga, AO, Kane, JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf) 1999;51:119.
Leslie, H, Courtney, CH, Bell, PM, et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001;86:2743.
Strachan, MW, Teoh, WL, Don-Wauchope, AC, et al. Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol (Oxf) 2003;59:339.
Gibney, J, Smith, TP, McKenna, TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005;62:633.
Gomez, F, Reyes, FI, Faiman, C. Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med 1977;62:648.
Schlechte, J, Sherman, B, Halmi, N, et al. Prolactin-secreting pituitary tumors in amenorrheic women: a comparative study. Endocr Rev 1980;1:295.
Seppala, M, Hirvonen, E, Ranta, T. Hyperprolactinemia and luteal insufficiency. Lancet 1976;1:229.
Corenblum, B, Fairaudeau, N, Shewchux, AB. Prolactin hypersecretion and short luteal phase defects. Obstet Gynecol 1976;47:486.
Biller, BMK, Baum, HBA, Rosenthal, DI, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992;75:692.
Schlechte, J, Walkner, L, Kathol, M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992;75:698.
Colao, A, Di Somma, C, Loche, S, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 2000;52:319.
Kleinberg, DL, Noel, GL, Frantz, AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 1977; 296:589.
Carter, JN, Tyson, JE, Tolis, G, et al. Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 1978;299:847.
Segal, S, Yaffe, H, Laufer, N, Ben-David, M. Male hyperprolactinemia: effects on fertility. Fertil Steril 1979;32:556.
Di Somma, C, Colao, A, Di Sarno, A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998;83:807.
Casanueva, FF, Molitch, ME, Schlechte, JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265.
St-Jean, E, Blain, F, Comtois, R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996;44:305.
Petakov, MS, Damjanovic, SS, Nikolic-Durovic, MM, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998;21:184.
Barkan, AL, Chandler, WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the “high-dosehook effect”: case report. Neurosurgery 1998;42:913.
Casanueva, FF, Molitch, ME, Schlechte, JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265.
Schlechte, J, Dolan, K, Sherman, B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989;68:412.
Sisam, DA, Sheehan, JP, Sheeler, LR. The natural history of untreated microprolactinoma. Fertil Steril 1987;48:67.
Costello, RT. Subclinical adenoma of the pituitary gland. Am J Pathol 1936;12:191.
Kraus, HE. Neoplastic diseases of the human hypophysis. Arch Pathol 1945;39:343.
Burrow, GN, Wortzman, G, Rewcastle, NB, Holgate, RC, Kovacs, K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. New Eng J Med 1981;304:156.
Vance, ML, Evans, WS, Thorner, MO. Drugs five years later. Bromocriptine. Ann Intern Med 1984;100:78.
Webster, J, Piscitelli, MD, Polli, A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904.
Biller, BMK, Molitch, ME, Vance, ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338.
Verhelst, J, Abs, R, Maiter, D, et al. Cabergoline in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1999;84:2518.
Rizk, B. Treatment of ovarian hyperstimulation syndrome. In Rizk, B (Ed.), Ovarian Hyperstimulation Syndrome. Cambridge, New York: Cambridge University Press, 2006; Chapter 8, pp. 200–26.
Kleinberg, DL, Boyd, AE 3rd., Wardlaw, S, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983;309:704.
Schade, R, Andersohn, F, Suissa, S, Haverkamp, W, Garbe, E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007 Jan 4;356(1):29–38.
Zanettini, R, Antonini, A, Gatto, G, Gentile, R, Tesei, S, Pezzoli, G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007 Jan 4;356(1):39–46.
Simonis, G, Fuhrmann, JT, Strasser, RH. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Mov Disord. 2007 Oct 15;22(13):1936–42.
Antonini, A, Poewe, W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007 Sep;6(9):826–9.
Kletzky, OA, Vermesh, M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil Steril. 1989;51:269.
Motta, T, Vincentiis, S, Marchini, M, et al. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil Steril. 1996;65:440.
Leong, KS, Foy, PM, Swift, AC, et al. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf) 2000;52:43.
Vance, ML, Lipper, M, Klibanski, A, et al. Treatment of prolactin secreting pituitary macroadenomas with the long acting nonergot dopamine agonist CV 205502. Ann Intern Med. 1990;112:668.
Beckers, A, Petrossians, P, Abs, R, et al. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases. J Clin Endocrinol Metab. 1992;75:275.
,, Lely, AL, Brownell, J, Lamberts, SW. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab. 1991;72:1136.
Molitch, ME. Macroprolactinoma size reduction with dopamine agonists. Endocrinologist. 1997;7:390.
Molitch, ME, Elton, RL, Blackwell, RE, et al. Bromocriptine as primary therapy for prolactin secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60:698.
Moster, ML, Savino, PJ, Schatz, NJ, et al. Visual function in prolactinoma patients treated with bromocriptine. Ophthalmology. 1985;92:1332.
Rosa, M, Colao, A, Di Sarno, A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol. 1998;138:286.
Rosa, M, Zarrilli, S, Vitale, G, et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab. 2004;89:621.
Colao, A, Vitale, G, Cappabianca, P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89:1704.
Warfield, A, Finkel, DM, Schatz, NJ, et al. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. Ann Intern Med. 1984;101:783.
Turkalj, I, Braun, P, Krupp, P, et al. Surveillance of bromocriptine in pregnancy. JAMA. 1982;247:1589.
Robert, E, Musatti, L, Piscitelli, G, et al. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10:333.
Ricci, E, Parazzini, F, Motta, T, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002;16:791.
Liuzzi, A, Dallabonzana, D, Oppizzi, G, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656.
Colao, A, Di Sarno, A, Cappabianca, P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003;349:2023.
Thorner, MO, Perryman, RL, Rogol, AD, et al. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981;53:480.
Van't Verlaat, JW, Croughs, RJ. Withdrawal of bromocriptine after long term therapy for macroprolactinomas: effect on plasma prolactin and tumor size. Clin Endocrinol 1991;34:175.
Passos, VQ, Souza, JJ, Musolino, NR, Bronstein, MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002; 87:3578.
Feigenbaum, SL, Downey, , Wilson, CB, et al. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab 1996;81:1711.
Randall, RV, Laws, ER Jr., Abboud, CF, et al. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas: results in 100 patients. Mayo Clin Proc 1983;58:108.
Serri, O, Rasio, E, Beauregard, H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983;309:280.
Schlechte, JA, Sherman, BM, Chapler, FK, et al. Long-term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J Clin Endocrinol Metab 1986;62:1296.
Ciric, I, Ragin, A, Baumgartner, C, Pierce, D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997;40:225.
Littley, MD, Shalet, SM, Reid, H, et al. The effect of external pituitary irradiation on elevated serum prolactin levels in patients with pituitary macroadenomas. Q J Med 1991;81:985.
Tsagarakis, S, Grossman, A, Plowman, PN, et al. Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clin Endocrinol 1991;34:399.
Snyder, PJ, Fowble, BF, Schatz, NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986;81:457.